Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PDS Biotechnology CorpPDSB · Entity 7939 | Director | January 12, 2026 | March 03, 2026 |
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | Director | June 22, 2026 | June 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PDS Biotechnology Corp
Report date January 12, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2036-01-12 | Direct | 54,876 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 54,876 · Balance 54,876 F1: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date.
RIGEL PHARMACEUTICALS INC
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,125 |
Reported balance
After 2026-06-22 transaction · row 1
1 source rowRow 1 · 2026-06-22 · Sale · Disposed 2,500 · Balance 10,125 F1: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025. F2: The shares sold in this transaction were sold to cover applicable tax withholding obligations incurred upon the vesting of restricted stock units and were not sold for investment purposes. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025.
F2: The shares sold in this transaction were sold to cover applicable tax withholding obligations incurred upon the vesting of restricted stock units and were not sold for investment purposes.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aclaris Therapeutics, Inc.
Report date January 03, 2022 · Filed January 05, 2022
Section 16 reporting ended · disclosed 2022-01-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 160,214 |
Ending reported balance
After 2022-01-03 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2022-01-03 · Exercise / conversion · Acquired 3,875 · Balance 118,571 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Row 2 · 2022-01-03 · Exercise / conversion · Acquired 27,905 · Balance 146,476 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Row 3 · 2022-01-03 · Exercise / conversion · Acquired 6,638 · Balance 153,114 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Row 4 · 2022-01-03 · Exercise / conversion · Acquired 7,100 · Balance 160,214 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-01-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-01-03 · Exercise / conversion · Disposed 3,875 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2: Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited. F3: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-01-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-01-03 · Exercise / conversion · Disposed 27,905 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2: Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited. F4: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-01-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-01-03 · Exercise / conversion · Disposed 7,100 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2: Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited. F6: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-01-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-01-03 · Exercise / conversion · Disposed 6,638 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2: Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited. F5: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2: Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited.
F3: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
F4: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
F5: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
F6: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2021 Filed May 6, 2021 00:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 13,721 | $23.61 | $323,891.07 |
DisclosureSEC source: 0001209191-21-030491 · doc4.xml · nonDerivative · entry 5 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,897 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.17 to $24.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2021 Filed May 6, 2021 00:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 15,000 | $10.66 | $159,900.00 |
DisclosureSEC source: 0001209191-21-030491 · doc4.xml · nonDerivative · entry 4 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2021 Filed May 6, 2021 00:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $10.66 | $0.00 |
DisclosureSEC source: 0001209191-21-030491 · doc4.xml · derivative · entry 10 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,416 Underlying: Common Stock · 65,416 shares Expires 2025-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option is fully vested. Read SEC document |
| May 03, 2021 Filed May 6, 2021 00:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 4,339 | $24.91 | $108,073.64 |
DisclosureSEC source: 0001209191-21-030491 · doc4.xml · nonDerivative · entry 3 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,618 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.82 to $24.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 03, 2021 Filed May 6, 2021 00:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 10,661 | $24.46 | $260,744.61 |
DisclosureSEC source: 0001209191-21-030491 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,957 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.82 to $24.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 03, 2021 Filed May 6, 2021 00:04 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 15,000 | $10.66 | $159,900.00 |
DisclosureSEC source: 0001209191-21-030491 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2021 Filed Nov 22, 2021 21:03 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GiftCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-066084 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,696 Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:39 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 6,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017544 · doc4.xml · derivative · entry 8 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,914 Underlying: Common Stock · 6,637 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F6 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F6 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:39 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 1,906 | $23.25 | $44,314.50 |
DisclosureSEC source: 0001209191-21-017544 · doc4.xml · nonDerivative · entry 4 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,618 F2 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 01:39 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 6,637 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-017544 · doc4.xml · nonDerivative · entry 3 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:39 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 17,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017544 · doc4.xml · derivative · entry 7 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,350 Underlying: Common Stock · 17,175 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F5 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:39 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 28,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017544 · doc4.xml · derivative · entry 6 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,400 Underlying: Common Stock · 28,400 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:39 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 99,500 | $0.00 Strike: $24.06 | $0.00 |
DisclosureSEC source: 0001209191-21-017544 · doc4.xml · derivative · entry 5 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,500 Underlying: Common Stock · 99,500 shares Expires 2031-02-28 F3 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of the grant date, subject to Reporting Person's continuous service through each such date. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:39 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 4,934 | $24.06 | $118,712.04 |
DisclosureSEC source: 0001209191-21-017544 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,887 F2 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:39 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 17,175 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-017544 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:26 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 3,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007372 · doc4.xml · derivative · entry 3 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,875 Underlying: Common Stock · 3,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:26 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 1,318 | $21.35 | $28,139.30 |
DisclosureSEC source: 0001209191-21-007372 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,646 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:26 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 3,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-007372 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 22:06 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 1,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064122 · doc4.xml · derivative · entry 3 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,734 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On December 15, 2016, the reporting person was granted 13,866 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vested in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: On December 15, 2016, the reporting person was granted 13,866 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vested in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 22:06 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 498 | $4.59 | $2,285.82 |
DisclosureSEC source: 0001209191-20-064122 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,089 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 22:06 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 1,734 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-064122 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 22:38 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 3,033 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001140361-20-014769 · form4.xml · derivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,033 Underlying: Common Stock · 3,033 shares Expires 2030-06-23 F1 · derivative.exercise_date: One third of the shares underlying the option shall vest upon each of the first, second, and third anniversaries of the date of grant, such that the option will be fully vested on June 23, 2023. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:42 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 33,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034060 · doc4.xml · derivative · entry 3 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,189 Underlying: Common Stock · 33,188 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:42 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 9,534 | $1.32 | $12,584.88 |
DisclosureSEC source: 0001209191-20-034060 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,853 F2 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:42 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 33,188 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-034060 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:22 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 26,551 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016073 · doc4.xml · derivative · entry 6 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,551 Underlying: Common Stock · 26,551 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F6 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F6 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:22 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 66,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016073 · doc4.xml · derivative · entry 5 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,377 Underlying: Common Stock · 66,377 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F5 · derivative.expiration_date: The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:22 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 92,928 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001209191-20-016073 · doc4.xml · derivative · entry 4 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,928 Underlying: Common Stock · 92,928 shares Expires 2030-03-01 F4 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of the grant date, subject to Reporting Person's continuous service through each such date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:22 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 17,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016073 · doc4.xml · derivative · entry 3 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,525 Underlying: Common Stock · 17,175 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:22 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 4,779 | $1.26 | $6,021.54 |
DisclosureSEC source: 0001209191-20-016073 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,199 F2 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 21:22 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 17,175 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-016073 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 21:30 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001140361-20-003908 · form4.xml · derivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-02-21 F1 · derivative.exercise_date: One-third (1/3) of the shares underlying the option shall vest upon each of the first, second and third anniversaries of the date of grant, such that the option will be fully vested on February 21, 2023. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 00:11 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 3,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-006666 · doc4.xml · derivative · entry 3 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,750 Underlying: Common Stock · 3,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 00:11 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 1,318 | $1.28 | $1,687.04 |
DisclosureSEC source: 0001209191-20-006666 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,803 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 00:11 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 3,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-006666 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:17 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 1,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-061536 · doc4.xml · derivative · entry 3 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,075 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On December 18, 2015, the reporting person was granted 4,300 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: On December 18, 2015, the reporting person was granted 4,300 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:17 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 277 | $1.81 | $501.37 |
DisclosureSEC source: 0001209191-19-061536 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,246 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 21:17 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 1,075 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-061536 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 16:00 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 1,733 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-061067 · doc4.xml · derivative · entry 3 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,734 Underlying: Common Stock · 1,733 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On December 15, 2016, the reporting person was granted 13,866 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: On December 15, 2016, the reporting person was granted 13,866 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 16:00 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 497 | $1.80 | $894.60 |
DisclosureSEC source: 0001209191-19-061067 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,448 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 16:00 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 1,733 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-061067 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 23:13 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 68,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-015898 · doc4.xml · derivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,700 Underlying: Common Stock · 68,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 23:29 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 3,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-007485 · doc4.xml · derivative · entry 3 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,625 Underlying: Common Stock · 3,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 23:29 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 1,308 | $6.96 | $9,103.68 |
DisclosureSEC source: 0001209191-19-007485 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,212 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 23:29 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 3,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-007485 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 18, 2018 Filed Dec 21, 2018 02:59 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 1,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-063795 · doc4.xml · derivative · entry 3 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,075 Underlying: Common Stock · 1,075 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On December 18, 2015, the reporting person was granted 4,300 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: On December 18, 2015, the reporting person was granted 4,300 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| December 18, 2018 Filed Dec 21, 2018 02:59 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 306 | $6.30 | $1,927.80 |
DisclosureSEC source: 0001209191-18-063795 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,645 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
| December 18, 2018 Filed Dec 21, 2018 02:59 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 1,075 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-063795 · doc4.xml · nonDerivative · entry 1 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 15, 2018 Filed Dec 19, 2018 01:52 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 1,733 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-063369 · doc4.xml · derivative · entry 3 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,467 Underlying: Common Stock · 1,733 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On December 15, 2016, the reporting person was granted 13,866 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: On December 15, 2016, the reporting person was granted 13,866 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| December 15, 2018 Filed Dec 19, 2018 01:52 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 493 | $7.31 | $3,603.83 |
DisclosureSEC source: 0001209191-18-063369 · doc4.xml · nonDerivative · entry 2 Ali-Jackson Kamil · CIK 0001654337 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,876 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.